Digital Health Canada

digitalhealthcanada.com

Digital Health Canada connects, inspires, and educates the digital health professionals creating the future of health in Canada. Our members are a diverse community of accomplished, influential professionals working to make a difference in advancing healthcare through information technology. Digital Health Canada fosters network growth and connection; brings together ideas from multiple segments for incubation and advocacy; supports members through professional development at the individual and organizational level; and advocates for the Canadian digital health industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

news image

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

news image

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More

Industrial Impact

LEGEND BIOTECH ACHIEVES MILESTONE PAYMENTS IN BCMA CAR-T COLLABORATION WITH JANSSEN

Legend Biotech Corporation | February 14, 2022

news image

Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. Legend Biotech entered into the agreement with Janssen to d...

Read More

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More
news image

Industrial Impact

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More
news image

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More
news image

Industrial Impact

LEGEND BIOTECH ACHIEVES MILESTONE PAYMENTS IN BCMA CAR-T COLLABORATION WITH JANSSEN

Legend Biotech Corporation | February 14, 2022

Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. Legend Biotech entered into the agreement with Janssen to d...

Read More
news image

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More